08 August 2025
Intas Pharmaceuticals and its U.S. specialty arm, Accord BioPharma, have announced the successful acquisition of UDENYCA® (pegfilgrastim-cbqv) from Coherus BioSciences. This move strengthens their position as one of the world’s leading suppliers of pegfilgrastim biosimilars.
Key Highlights:
Biosimilar Expansion: UDENYCA, a pegfilgrastim biosimilar, helps reduce infection risk in cancer patients undergoing chemotherapy and improves survival after radiation exposure.
Multiple Formulations: Now available in three formats—autoinjector, on-body injector, and prefilled syringe—enhancing treatment convenience for patients. More than 1.4 million units have already been distributed, benefitting over 300,000 patients.
Smooth Transition: Employees from Coherus across sales, marketing, supply chain, and manufacturing have joined Accord, ensuring continuity and growth.
Global Leadership: Accord is already a leader in pegfilgrastim biosimilars in Europe and was the first to launch the autoinjector. The acquisition significantly boosts its U.S. and worldwide presence.
Management Commentary:
Binish Chudgar, Chairman & MD of Intas, said the deal cements the company’s global leadership in pegfilgrastim.
Chrys Kokino, U.S. President of Accord, called it a pivotal moment that strengthens their presence in the U.S. market.
Paul Tredwell, EVP of Accord EMENA, highlighted that offering UDENYCA in three formulations brings them closer to becoming the world’s leading pegfilgrastim supplier.
Intas Pharmaceuticals and its U.S. specialty arm, Accord BioPharma, have announced the successful acquisition of UDENYCA® (pegfilgrastim-cbqv) from Coherus BioSciences. This move strengthens their position as one of the world’s leading suppliers of pegfilgrastim biosimilars.
Key Highlights:
Biosimilar Expansion: UDENYCA, a pegfilgrastim biosimilar, helps reduce infection risk in cancer patients undergoing chemotherapy and improves survival after radiation exposure.
Multiple Formulations: Now available in three formats—autoinjector, on-body injector, and prefilled syringe—enhancing treatment convenience for patients. More than 1.4 million units have already been distributed, benefitting over 300,000 patients.
Smooth Transition: Employees from Coherus across sales, marketing, supply chain, and manufacturing have joined Accord, ensuring continuity and growth.
Global Leadership: Accord is already a leader in pegfilgrastim biosimilars in Europe and was the first to launch the autoinjector. The acquisition significantly boosts its U.S. and worldwide presence.
Management Commentary:
Binish Chudgar, Chairman & MD of Intas, said the deal cements the company’s global leadership in pegfilgrastim.
Chrys Kokino, U.S. President of Accord, called it a pivotal moment that strengthens their presence in the U.S. market.
Paul Tredwell, EVP of Accord EMENA, highlighted that offering UDENYCA in three formulations brings them closer to becoming the world’s leading pegfilgrastim supplier.
Stay Connected, Stay Informed –
Don’t miss out on exclusive updates, market trends, and real-time investment opportunities. Be the first to know about the latest unlisted stocks, IPO announcements, and curated Fact Sheets, delivered straight to your WhatsApp.